Megyesfalvi Z, Gay CM, Popper H, et al. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin. 2023;73(6):602–52.

Google Scholar 

Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 2015;121(5):664–72.

Article  CAS  PubMed  Google Scholar 

National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Small cell lung cancer version 2 2026. 2025. http://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed 21 Jan 2026.

Dingemans A-M, Fruh M, Ardizzoni A, et al. Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(7):839–53.

Article  PubMed  PubMed Central  Google Scholar 

Jett JR, Schild SE, Kesler KA, et al. Treatment of small cell lung cancer: diagnosis and management of lung cancer 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(Suppl 5):e400S – e419.

Article  CAS  PubMed  Google Scholar 

Bogart J, Wang X, Masters G, et al. High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer: CALGB 30610 (Alliance)/RTOG 0538. J Clin Oncol. 2023;41(13):2394–402.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salama JK, Hodgson L, Pang H, et al. A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. J Thorac Oncol. 2013;8(8):1043–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Senan S, Okamoto I, Lee GW, et al. Design and rationale for a phase III, randomized, placebo-controlled trial of durvalumab with or without tremelimumab after concurrent chemoradiotherapy for patients with limited-stage small-cell lung cancer: the ADRIATIC study. Clin Lung Cancer. 2020;21(2):e84–8.

Article  CAS  PubMed  Google Scholar 

Cheng Y, Spigel DR, Cho BC, et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med. 2024;391(14):1313–27.

Article  CAS  PubMed  Google Scholar 

Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–86.

Article  PubMed  Google Scholar 

AstraZeneca Pharmaceuticals LP. Imfinzi® (durvalumab) injection, for intravenous use: US prescribing information 2025. http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761069s052lbl.pdf. Accessed 21 Jan 2026.

Al-Salama ZT. Durvalumab: a review in extensive-stage SCLC. Target Oncol. 2021;16(6):857–64.

Article  PubMed  PubMed Central  Google Scholar 

Genentech. Tecentriq® (atezolizumab) injection, for intravenous use. 2024. http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761034s059lbl.pdf. Accessed 21 Jan 2026.

AstraZeneca AB. Imfinzi 50 mg/ml concentrate for solution for infusion: summary of product characteristics. 2025. http://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf. Accessed 21 Jan 2026.

AstraZeneca Canada Inc. Imfinzi® (durvalumab for injection): notice of compliance. 2025. http://pdf.hres.ca/dpd_pm/00080178.PDF. Accessed 21 Jan 2026.

AstraZeneca UK Limited. Imfinzi 50 mg/ml concentrate for solution for infusion: summary of product characteristics. 2025. http://www.medicines.org.uk/emc/product/9495/smpc/print. Accessed 21 Jan 2026.

Cheng Y, Wang Q, Fang J, et al. Durvalumab (D) as consolidation therapy for limited-stage small-cell lung cancer (LS-SCLC): ADRIATIC China subgroup analysis [abstract no. 336P]. J Thorac Oncol. 2025;20(3 Suppl 1):S203–4.

Article  Google Scholar 

Zenke Y, Shiraishi Y, Goto Y, et al. Durvalumab post concurrent chemoradiotherapy in Japanese patients with limited‐stage small‐cell lung cancer in the phase 3 ADRIATIC trial. Cancer Sci. 2025;116(11):3171–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Novello S, Cheng Y, Spigel D, et al. Patient-reported outcomes with consolidation durvalumab versus placebo following concurrent chemoradiotherapy in limited-stage small-cell lung cancer: results from the phase 3 ADRIATIC trial. J Thorac Oncol. 2026. https://doi.org/10.1016/j.jtho.2026.103564.

Iyengar P, Cheng Y, Spigel D, et al. Safety profile of durvalumab (D) as consolidation treatment (tx) in limited-stage small-cell lung cancer (LSSCLC) in ADRIATIC: focus on pneumonitis and immune mediated adverse events (imAEs) [abstract no. LBA 13]. Int J of Radiat Oncol Biol Phys. 2024;120(2 Suppl):S8-9.

Article  Google Scholar 

Kalemkerian GP, Khurshid H, Ismaila N, et al. Erratum: systemic therapy for small cell lung cancer: ASCO guideline rapid recommendation update clinical insights. JCO Oncol Pract. 2025;43(1):101–5.

CAS  Google Scholar 

Rudin CM, Ismaila N, Hann CL, et al. Treatment of small-cell lung cancer: American Society of Clinical Oncology endorsement of the American College of Chest Physicians guideline. J Clin Oncol. 2015;33(34):4106–11.

Article  CAS  PubMed  Google Scholar 

European Society for Medical Oncology. Durvalumab ADRIATIC ESMO-MCBS Scorecard. 2024. http://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards?scorecard=483. Accessed 21 Jan 2026.

Liu K, Zhu Y, Zhu H. International cost-effectiveness analysis of durvalumab consolidation treatment after chemoradiotherapy for patients with limited-stage small-cell lung cancer. Transl Lung Cancer Res. 2025;14(8):2942–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jani CT, Manoharan A, Han S, et al. Cost-effectiveness analysis of durvalumab in limited-stage small cell lung cancer in the United States. JCO Glob Oncol. 2025;11:e2500225.

Article  PubMed  Google Scholar 

Zhang H, Liu Y, Cai B, et al. Durvalumab consolidation therapy in patients with stage III small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis. Front Oncol. 2025;15:1643022.

Article  PubMed  PubMed Central  Google Scholar 

National Institute for Health and Care Excellence (NICE). Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy. 2025. http://www.nice.org.uk/guidance/ta1099. Accessed 21 Jan 2026.

AstraZeneca. Imfinzi approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer [media release]. 5 December 2024. http://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-approved-in-us-for-limited-stage-sclc.html.

AstraZeneca. Imfinzi approved in the EU as first and only immunotherapy for limited-stage small cell lung cancer [media release]. 17 March 2025. http://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-approved-in-eu-for-limited-stage-sclc.html.

Hann C, Cheng Y, Spigel D, et al. Durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC): outcomes by PD-L1 expression in ADRIATIC [abstract no. CT094]. Cancer Res. 2025;85(8 Suppl 2).

Article  Google Scholar 

Senan S, Cheng Y, Spigel DR, et al. Patterns of disease progression with durvalumab (D) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC): results from ADRIATIC [abstract no. 297MO]. J Thorac Oncol. 2025;20(3 Suppl 1):S181–2.

Article  Google Scholar 

Jin X, Zhao W, Li G, et al. Immunotherapy for limited-stage small cell lung cancer: innovative treatments and future perspectives. Cancer Control. 2025. https://doi.org/10.1177/10732748251334434.

Ruysscher D, Wauters E, Jendrossek V, et al. Diagnosis and treatment of radiation induced pneumonitis in patients with lung cancer: an ESTRO clinical practice guideline. Radiother Oncol. 2025;207:110837.

Article  PubMed  Google Scholar 

Stewart R, Morrow M, Hammond SA, et al. Identification and characterization of MEDI4736, an antagonistic anti–PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3(9):1052–62.

Article  CAS  PubMed  Google Scholar 

European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). Imfinzi assessment report. 2018. http://www.ema.europa.eu/en/documents/assessment-report/imfinzi-epar-public-assessment-report_en.pdf. Accessed 21 Jan 2026.